An interventional study of In-hospital staged complete revascularization and Out-of-hospital staged complete revascularization in Myocardial Infarction (MI), sponsored by Chonnam National University Hospital. Recruiting at 30 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Chonnam National University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Myocardial Infarction by Chonnam National University Hospital — 7 open to participants now, 8 under way, none of them phase 3. Myocardial Infarction · Chonnam National University Hospital.
Among the 12 studies in Myocardial Infarction by Chonnam National University Hospital, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 with no phase, and was the 11th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →7 of the 12 studies in Myocardial Infarction by Chonnam National University Hospital are open now, in 1 country. Recruiting first, the newest first:
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,252 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 860 across the 11 interventional studies, 150 across the 1 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chonnam National University Hospital is the lead sponsor of 72 studies on the registry; 15 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Myocardial Infarction by Chonnam National University Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, multicenter, open-label, superiority trial will enroll patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. Following successful percutaneous coronary intervention (PCI) of the infarct-related artery (IRA), patients who meet the eligibility criteria will be randomized in a 1:1 ratio to either in-hospital staged complete revascularization with PCI of non-IRA lesions performed on a separate day during hospitalization, at least 48 hours after PCI of the IRA, or out-of-hospital staged complete revascularization with PCI of non-IRA lesions performed after discharge between 15 and 45 days of randomization. In both groups, non-IRA lesions with 50-69% stenosis will be evaluated using FFR.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the in-hospital staged complete revascularization group, PCI of non-IRA lesions will be performed on a separate day during the index hospitalization, at least 48 hours after PCI of the IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Procedure: In-hospital staged complete revascularization
In the out-of-hospital staged complete revascularization group, PCI of non-IRA lesions will be performed after discharge and between 15 and 45 days of randomization. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Procedure: Out-of-hospital staged complete revascularization
PCI of non-IRA lesions will be performed on a separate day during the index hospitalization, at least 48 hours after PCI of the IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
PCI of non-IRA lesions will be performed after discharge and between 15 and 45 days of randomization. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Composite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization
Composite of all-cause death, nonfatal myocardial infarction, or all unplanned
Time frame: At 12 months after randomization
Composite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization
Composite of all-cause death, nonfatal myocardial infarction, or all unplanned
Time frame: At 1, 6, 24, 36, 48, and 60 months after randomization
All-cause death
All-cause death
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Nonfatal myocardial infarction
Nonfatal myocardial infarction
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
All unplanned revascularization
All unplanned revascularization
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Cardiac death
Cardiac death
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Non-cardiac death
Non-cardiac death
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Nonfatal spontaneous myocardial infarction
Nonfatal spontaneous myocardial infarction
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Nonfatal procedure-related myocardial infarction
Nonfatal procedure-related myocardial infarction
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Target-lesion revascularization
Target-lesion revascularization
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Target-vessel revascularization
Target-vessel revascularization
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Non-target vessel revascularization
Non-target vessel revascularization
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Hospitalization for unstable angina
Hospitalization for unstable angina
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Hospitalization for heart failure
Hospitalization for heart failure
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Stent thrombosis
Stent thrombosis
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Stroke
Stroke
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Major bleeding
Major bleeding
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Contrast-induced nephropathy
Contrast-induced nephropathy
Time frame: At hospital discharge (up to 30 days)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jul 2031, 59 months after the start.
Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 59 months is above that.
Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Oct 23, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chonnam National University Hospital